Peroxitech is a biotech start-up out of the University of Pennsylvania. Our lead program is a breakthrough treatment for acute lung injury. The most pressing indication for our lead candidate is COVID-19 induced acute lung injury. In these patients, acute lung injury is the leading cause of death. Our co-founders and scientists discovered a new pathway and a novel drug to treat and prevent acute lung injury.
